High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

Bone Marrow Transplantation
P LjungmanG Oberg

Abstract

The aim of this study was to investigate the importance of busulfan concentrations for short- and long-term survival in autologous (ABMT) and allogeneic (BMT) bone marrow transplant recipients. One hundred and seventy-three patients were included in the study; 87 ABMT and 85 BMT patients. All patients received busulfan 1 mg/kg four times daily for 4 days followed by cyclophosphamide 60 mg/kg/day for 2 days. Busulfan concentrations were measured and the mean concentration calculated for each patient. There was no difference in busulfan concentrations between BMT and ABMT patients. Patients who died before day 100 had significantly higher busulfan concentrations than patients surviving beyond day 100 (719 ng/ml vs 589 ng/ml; P < 0.02). BMT patients who had busulfan concentrations in the highest quartile had significantly worse disease-free survival (DFS) and survival compared to other patients. The transplant-related mortalities (TRM) at 100 days were 29 and 14% in patients in the highest quartile and remaining patients, respectively. There was no difference in relapse incidence. High busulfan concentrations were associated with increased TRM but no difference in either survival or DFS could be found for the ABMT patients. Monito...Continue Reading

Citations

Oct 19, 1999·Medical Oncology·M Hassan
Jan 23, 2008·Bone Marrow Transplantation·C F Craddock
Oct 19, 2000·Anti-cancer Drugs·A D HuitemaJ H Beijnen
Sep 8, 2000·Clinical Pharmacokinetics·J S McCuneJ T Slattery
May 19, 2010·Biomarkers in Medicine·Judith Meza-Junco, Michael B Sawyer
Oct 10, 2001·Therapeutic Drug Monitoring·A TabakN Krivoy
Aug 15, 2000·Therapeutic Drug Monitoring·M HassanO Ringdén
May 16, 2012·Therapeutic Drug Monitoring·Mohamed SaleemJennifer H Martin
Aug 7, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·J E PerisF Torres-Molina
Nov 17, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·M H QuerninE J Aigrain
Nov 20, 2012·Expert Opinion on Drug Metabolism & Toxicology·Ariane Galaup, Angelo Paci
Sep 26, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ji Won LeeHyo Seop Ahn
Apr 24, 2007·Best Practice & Research. Clinical Haematology·Johan Aschan
Sep 11, 2009·Pediatric Blood & Cancer·Donna A WallUNKNOWN Pediatric Blood, Marrow Transplant Consortium
Jan 9, 2003·Clinics in Liver Disease·Vijayrama Poreddy, Laurie D DeLeve
Dec 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Imke H BartelinkJaap J Boelens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.